

8 May 2019

RENOUNCEABLE RIGHTS ISSUE TO RAISE UP TO \$2.55 MILLION

- 1 for 5 Renounceable Rights Issue to raise up to \$2.55 million
- Attractively priced at 1.1 cents per share
- Discount of 39% to the last price of 1.8 cents, 37% to the 30 day VWAP and 43% to the 90 day VWAP
- With every 2 New Shares, shareholders will receive one free attaching New Option
- New Options will have Exercise Price of 2.0 cents, term of 18 months and be listed
- Shareholders can trade their rights and apply for additional shares and options
- Rights to start trading from 10 May 2019
- Directors intend to participate
- Chairman and Director sub-underwriting for additional allocation from shortfall
- Funds to be used primarily to advance near-term commercialisation opportunities in Battery and Life Sciences divisions

Anteo Diagnostics Limited (ASX: ADO) (“Anteo” or “the Company”) is pleased to announce a \$2.55 million Renounceable Rights Issue to fund the growth and development of the Battery and Life Sciences divisions. The issue is partially underwritten to \$1 million by CPS Capital Group Pty Ltd, and sub-underwritten by Chairman Dr Jack Hamilton and Director Mr Matt Sanderson for \$180,000.

Under the offer, shareholders will be offered 1 New Share for every 5 Existing Shares held on 10 May 2019 (“Record Date”), with 1 attaching listed Option, exercisable at \$0.02 and expiring 18 months from issue, for every 2 New Shares subscribed.

Assuming full subscription under the Rights Issue and receipt of an expected R&D claim, Anteo will be well-funded with up to \$4.9 million available to:

- Drive our Li-ion Battery anode Research and Development programme and realise commercial opportunities for our high-performance Silicon Graphite Composite product.
- Grow our Point of Care (POC) business development capability and build a global distribution network to commercialise our increasingly strong portfolio of POC products and services.
- Protect and strengthen our suite of Anteo Patents and IP in both the Battery and Life Science segments.
- Expand the manufacturing capacity at the Company’s Queensland facility
- Contribute towards working capital requirements and costs of the offer.

Chief Executive Harley Frankfurt said: *“We are pleased to give shareholders the opportunity to participate in Anteo’s growth and development through this issue. When completed, we will have the necessary financial flexibility to capitalise on some very exciting commercialisation developments for Anteo’s unique surface coating technology in the Battery and Life Science sectors. Solid progress is being made across both markets and we expect to report a steady stream of developments throughout the remainder of calendar 2019.*”

Anteo is entering a very exciting phase and we are genuinely energised about the prospects we are now pursuing. We look forward to delivering on these.”

The issue price under the rights issue represents a discount of:

- 39% to the Company’s last close of \$0.018 on the ASX;
- 37% to the Company’s 15 day and 30 day VWAP of \$0.0175; and
- 43% to the Company’s 90 day VWAP of \$0.0192.

The Rights Issue is open to all eligible shareholders who have a registered address within Australia or New Zealand, and who hold Shares on the Record Date. The Rights Issue will close on 30 May 2019 (unless extended), and eligible shareholders can apply for shortfall in excess of their entitlement.

All New Shares issued will rank equally with existing shares on issue and the Company will apply for quotation of the New Shares and Options. A prospectus in relation to the Rights Issue was lodged with ASIC on 8 May 2019 and, together with a personalised entitlement acceptance form, will be sent to eligible shareholders shortly after the Record Date.

Eligible shareholders should consider the prospectus in deciding whether to acquire securities under the Rights Issue, and will need to complete the personalised entitlement and acceptance form that will accompany the prospectus. The following are indicative dates in respect of the capital raising:

Event	Date
Notice sent to shareholders	9 May 2019
Ex entitlement date Rights trading commences on a deferred settlement basis	10 May 2019
Record Date for determining entitlements (5:00pm EST)	13 May 2019
Prospectus and personalised Entitlement and Acceptance Forms sent out to Eligible Shareholders	16 May 2019
Rights trading ends	23 May 2019
Closing date of entitlement issue (5:00pm EST)	30 May 2019
ASX notified of under subscriptions	4 June 2019
Issue date.	6 June 2019

These dates are indicative only and may change, subject to the Corporations Act and Listing Rules.

ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX)

Anteo Group is a surface chemical company with Intellectual Property (“IP”) in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company’s purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Anteo’s customers operate in the life sciences, diagnostics, energy and medical devices markets.

For more information, please contact:

Harley Frankfurt, Chief Executive Officer, Anteo Diagnostics Limited: +61 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

Follow Anteo Diagnostics on Twitter:



<https://twitter.com/AnteoDX> or visit www.anteotech.com